GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
AstraZeneca on Wednesday announced that it had filed separate patent infringement actions in the United States District Court, Delaware, against seven generic drug manufacturers, which have submitted abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) seeking marketing authorisation for Crestor.
Global investment firm Citigroup is bullish on Indian equity markets.
The BCCI will be expecting the two new IPL franchises to go for Rs 7000 crore to Rs 10,000 crore each at the bidding process which begins in Dubai on Monday.
After making big-ticket acquisitions abroad, leading Indian pharmaceutical companies like Dr Reddy's Laboratories, Ranbaxy Laboratories, and Aurobindo Pharma are rapidly shifting production to their Indian facilities.
In comparison, Indian companies received only 23 out of 139 final approvals (16.54 per cent) in the corresponding period in 2006.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
With sales of over Rs 12,240 crore in nine months of the current financial year, it is ahead of Rs 11,580 crore recorded by Lupin but behind Sun Pharma, which reported Rs 19,350 crore sales.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
Telangana chief minister K Chandrasekhar Rao on Wednesday announced the establishment of a massive industrial park dedicated to pharmaceutical manufacturing activities.
Indian companies have made acquisitions of $1 billion so far in January
Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.
The S&P BSE 500 index, which accounts for 94% market capitalisation of BSE listed companies, has gained 45% from its March 24 low. However, out of the BSE 500 index stocks, 225 have underperformed the index by gaining less than the broader index during this period.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
The BSE Mid-Cap index was currently up 0.81%.
This is a shift as until recent months, fund managers were reducing exposure to these sectors.
Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.
The country's drug companies have attracted the highest number of enforcements from the American drug regulator in 2013, a year that has seen the US Food and Drug Administration turning stricter to ensure compliance levels and quality of medicines.
Ajit Mishra, vice president, research, Religare Broking, answers your queries.
The FMCG index gained more than 1% on the back of stellar gains in ITC.
IT, pharma and FMCG stocks are the top performers in 2013.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
n the broader market, both the BSE Midcap and Smallcap indices, were up 1.2% and 0.7% each.
Investors turn their attention to export-driven sectors.
FDA allows Teva to launch Nexium generic; Cipla, which supplies formulation, to gain
Revival in domestic business should also help overall revenue growth.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
And when an inspector asked about the contents of unlabelled vials in the laboratory glassware washing area, a plant worker dumped them down a sink and said the contents could not be determined, according to a July 18 letter from the US Food and Drug Administration to Wockhardt, which makes sterile injectable drugs and various forms of insulin.
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances